Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
Publié dansOsteoporosis international, vol. 33, no. 12, p. 2527-2536
Date de publication2022-12
Date de mise en ligne2022-09-29
Résumé
Mots-clés
- Anabolics
- Clinical fractures
- Clinical trials
- Osteoporosis
- Humans
- Female
- Denosumab / adverse effects
- Double-Blind Method
- Bone Density
- Bone Density Conservation Agents / adverse effects
- Osteoporotic Fractures / chemically induced
- Osteoporosis, Postmenopausal / complications
Structure d'affiliation
Groupe de recherche
Financement
- UCB Pharma -
- Amgen Inc -
Citation (format ISO)
LANGDAHL, Bente et al. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. In: Osteoporosis international, 2022, vol. 33, n° 12, p. 2527–2536. doi: 10.1007/s00198-022-06544-2
Fichiers principaux (1)
Article (Published version)
Fichiers secondaires (1)
Identifiants
- PID : unige:167403
- DOI : 10.1007/s00198-022-06544-2
- PMID : 36173415
- PMCID : PMC9652294
Jeu de données
ISSN du journal0937-941X